
|Videos|July 13, 2023
THOR: Erdafitinib vs Chemotherapy in Metastatic Urothelial Cancer with FGFR Alterations
Expert oncologists offer insights on recent data from the THOR trial, which compared erdafitinib with chemotherapy in patients with metastatic bladder cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















